Affimed (NASDAQ:AFMD) Cut to Hold at Cantor Fitzgerald

Cantor Fitzgerald lowered shares of Affimed (NASDAQ:AFMD) from a strong-buy rating to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.

AFMD has been the subject of several other research reports. HC Wainwright downgraded shares of Affimed from a “buy” rating to a “neutral” rating in a research note on Wednesday. Leerink Partnrs downgraded Affimed from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Company restated an “equal weight” rating and set a $0.10 price objective (down previously from $11.00) on shares of Affimed in a report on Tuesday. StockNews.com started coverage on Affimed in a research report on Sunday, May 11th. They issued a “sell” rating on the stock. Finally, Leerink Partners reiterated a “market perform” rating and set a $0.39 target price (down from $5.00) on shares of Affimed in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.90.

Affimed Stock Up 227.8%

AFMD stock opened at $0.28 on Wednesday. Affimed has a 12 month low of $0.07 and a 12 month high of $8.95. The company has a 50-day moving average price of $0.73 and a 200 day moving average price of $1.41. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Trading of Affimed

A hedge fund recently raised its stake in Affimed stock. Intellectus Partners LLC boosted its position in shares of Affimed (NASDAQ:AFMD) by 34.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 126,414 shares of the biopharmaceutical company’s stock after purchasing an additional 32,053 shares during the quarter. Intellectus Partners LLC owned about 0.79% of Affimed worth $150,000 as of its most recent filing with the Securities & Exchange Commission. 30.82% of the stock is currently owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.